Upregulated Immunogenic Cell-Death-Associated Gene Signature Predicts Reduced Responsiveness to Immune-Checkpoint-Blockade Therapy and Poor Prognosis in High-Grade Gliomas

Background: Immunogenic cell death (ICD) has emerged as a potential mechanism mediating adaptive immune response and tumor immunity in anti-cancer treatment. However, the signature of ICD in high-grade gliomas (HGGs) remains largely unknown, and its relevance to immunotherapies is still undetermined...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xin, Guo, Dongfang, Yang, Xi, Chen, Rui, Jiang, Qingming, Zeng, Zhen, Li, Yu, Li, Zhenyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688114/
https://www.ncbi.nlm.nih.gov/pubmed/36429083
http://dx.doi.org/10.3390/cells11223655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688114/
https://www.ncbi.nlm.nih.gov/pubmed/36429083
http://dx.doi.org/10.3390/cells11223655

Ejemplares similares